Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172695 | 1.00 | PDE4A (0.53) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL7065128 | 1.00 | PDE4A (0.53) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL9709097 | 0.98 | PDE4A (0.52) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL28352661 | 0.85 | PDE4A (0.52) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL686833 | 0.85 | PDE4A (0.47) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL516654 | 0.83 | PDE4A (0.45) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL11359344 | 0.82 | PDE4A (0.55) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL2673588 | 0.81 | TDP1 (0.48) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL872999 | 0.80 | PDE4A (0.57) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL27947756 | 0.80 | PDE4A (0.47) | PDE4ALMNATDP1L3MBTL1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318432-B1 | Photoresist residue removing liquid composition | KANTO KAGAKU (JP) | 2011-02-16 | — | — | EP | claimed |
| US-6864044-B2 | Photoresist residue removing liquid composition | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2005-03-08 | — | — | US | claimed |
| US-6610309-B2 | Vaccines; mixture of antigen and water solubility organometallic compound | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (S.E.P.P.I.C.) (FR) | 2003-08-26 | — | — | US | claimed |
| US-6342234-B1 | VACCINES | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHEMIQUES (SEPPIC) (FR) | 2002-01-29 | — | — | US | claimed |
| EP-1318432-B1 | Photoresist residue removing liquid composition | KANTO KAGAKU (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-6864044-B2 | Photoresist residue removing liquid composition | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2005-03-08 | — | — | US | disclosed |
| US-6689370-B1 | VACCINE ADJUVANT IS A ZINC, MANGANESE OR CALCIUM SALT OF GLUCONIC ACID, FRUCTOHEPTONIC ACID OR GLUCOHEPTONIC ACID | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (S.E.P.P.I.C.) (FR) | 2004-02-10 | — | — | US | disclosed |
| US-6610309-B2 | Vaccines; mixture of antigen and water solubility organometallic compound | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (S.E.P.P.I.C.) (FR) | 2003-08-26 | — | — | US | disclosed |
| US-20030143495-A1 | Photoresist residue removing liquid composition | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1318432-A1 | Photoresist residue removing liquid composition | Kanto Kagaku Kabushiki Kaisha (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-20020164359-A1 | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence | GANNE VINCENT (FR) | 2002-11-07 | — | — | US | disclosed |
| US-6342234-B1 | VACCINES | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHEMIQUES (SEPPIC) (FR) | 2002-01-29 | — | — | US | disclosed |
| US-20010033845-A1 | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence | GANNE VINCENT (FR) | 2001-10-25 | — | — | US | disclosed |
| US-6274149-B1 | FOR INCREASING IN IMMUNE RESPONSE | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (S.E.P.P.I.C.) (FR) | 2001-08-14 | — | — | US | disclosed |
| US-6251407-B1 | AND ADJUVANT SELECTED FROM MANGANESE GLUCONATE, CALCIUM GLUCONATE, ZINC GLUCONATE, CALCIUM FRUCTOHEPTONATE, ZINC GLUCOHEPTONATE, OR CALCIUM GLYCEROPHOSPHATE AND AN OILY PHASE ESTER OF ETHOXYLATED FATTY ACIDS; IMMUNOSTIMULATORY | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMQUE (FR) | 2001-06-26 | — | — | US | disclosed |
| US-6117432-A | ALUMINUM ACETATE OR SALICYLATE ADJUVANT | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (S.E.P.P.I.C.) (FR) | 2000-09-12 | — | — | US | disclosed |
| US-4975219-A | Comprising tannic acid and/or a salt, sugar, at least one member selected form aldonic acids of hexoses or salts and aldonic acid of heptose or salts; nontoxic | KURITA WATER INDUSTRIES, LTD. (JP) | 1990-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164359-A1 | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence | CD74, TP53, HLA-DRB1 | PDE4A 4609/4885LMNA 4847/4885TDP1 3585/4885 |
| US-20010033845-A1 | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence | CD74, TP53, HLA-DRB1 | PDE4A 4609/4885LMNA 4847/4885TDP1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.